Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healios KK Ord Shs HLOSF

Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.


PINL:HLOSF - Post by User

Comment by Camaronion Apr 20, 2011 12:06pm
239 Views
Post# 18461428

Book Value is pegged at $0.93

Book Value is pegged at $0.93
Acording to Stockhouse. TD has bk val at $1.20 or so. One analyst places a $2.10 spec buy rating on it and the company has a lot of resources and partners with deep pockets. Certainly seems like it worth a further risk to average down a bit for when the worm turns. Has an $8 per shr history when the resource was less defined. Really does seem like potential rising star. I have been in for a bout a year so far at avg cost of
.65. SOooooooooooo have the paper loss only so far, with the upside potential as the draw. I could be right or could be wrong................ really hating the wait to find out though. If big player are holding, I am holding. Obviously they are because the volume is anemic. Just there recent silver find should have been a catlyst in my mind but what do I know............. Hopefully $2.10 soon after release of re-estimate of VMS........................ woner if they are doing that to help define a take over offer from Hudbay??
<< Previous
Bullboard Posts
Next >>